Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol

INTRODUCTION: Patients with metastatic or locally advanced, non-resectable, grade 3 poorly differentiated gastroenteropancreatic (GEP) and lung neuroendocrine carcinomas (NECs) are usually treated with in first-line platinum compounds. There is no standard second-line treatment on progression. Accur...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:BMJ Open
Asıl Yazarlar: Bongiovanni, Alberto, Liverani, Chiara, Pusceddu, Sara, Leo, Silvana, Di Meglio, Giovanni, Tamberi, Stefano, Santini, Daniele, Gelsomino, Fabio, Pucci, Francesca, Berardi, Rossana, Lolli, Ivan, Bergamo, Francesca, Ricci, Sergio, Foca, Flavia, Severi, Stefano, Ibrahim, Toni
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Publishing Group 2020
Konular:
Oncology
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7371236/
https://ncbi.nlm.nih.gov/pubmed/32690499
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2019-034393
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller